Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia-Reference-Cited by-同舟云学术

Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia

Published:2017-06-01 Issue:6 Volume:2 Page:598
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Koren Michael J.¹,Sabatine Marc S.²,Giugliano Robert P.³,Langslet Gisle⁴,Wiviott Stephen D.³,Kassahun Helina⁵,Ruzza Andrea⁵,Ma Yuhui⁵,Somaratne Ransi⁵,Raal Frederick J.⁶

Affiliation:

1. Jacksonville Center for Clinical Research, Jacksonville, Florida

2. Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts3Deputy Editor, JAMA Cardiology

3. Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

4. Lipid Clinic, Oslo University Hospital, Oslo, Norway

5. Amgen Inc, Thousand Oaks, California

6. The Carbohydrate and Lipid Metabolism Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Parktown, Johannesburg, South Africa

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative effectiveness of different methods of prescribing rosuvastatin and ezetimibe in combination with PCSK9 inhibitors;Medical Herald of the South of Russia;2024-06-15

2. Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression;Current Medical Research and Opinion;2024-06-11

3. How safe are proprotein convertase subtilisinekexin type 9 inhibitors in diabetes?;Current Opinion in Lipidology;2024-03-20

4. Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature;Drugs;2024-01-25

5. PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke;Frontiers in Pharmacology;2024-01-11